Jennifer Butler

Jennifer Butler

Alston & Bird

Contact
View Bio
RSS

Latest Posts › Pharmaceutical Industry

Share:

Alston & Bird Healthcare Week in Review

Alston & Bird’s Week in Review provides a synopsis of the latest news in health care regulations, notices, and guidance; federal legislation and Congressional committee action; reports, studies, and analyses; and other health...more

12/10/2018  /  Department of Health and Human Services (HHS) , Food and Drug Administration (FDA) , Health Care Providers , PDUFA , Pharmaceutical Industry , Prescription Drugs

Alston & Bird Healthcare Week in Review

Alston & Bird’s Week in Review provides a synopsis of the latest news in health care regulations, notices, and guidance; federal legislation and Congressional committee action; reports, studies, and analyses; and other health...more

11/19/2018  /  Centers for Disease Control and Prevention (CDC) , Centers for Medicare & Medicaid Services (CMS) , Department of Health and Human Services (HHS) , Food and Drug Administration (FDA) , PDUFA , Pharmaceutical Industry

Alston & Bird Healthcare Week in Review

Alston & Bird’s Week in Review provides a synopsis of the latest news in health care regulations, notices, and guidance; federal legislation and Congressional committee action; reports, studies, and analyses; and other health...more

11/12/2018  /  Affordable Care Act , Centers for Medicare & Medicaid Services (CMS) , Children's Health Insurance Program (CHIP) , Department of Health and Human Services (HHS) , Food and Drug Administration (FDA) , MACPAC , PDUFA , Pharmaceutical Industry

Alston & Bird Healthcare Week in Review

Alston & Bird’s Week in Review provides a synopsis of the latest news in health care regulations, notices, and guidance; federal legislation and Congressional committee action; reports, studies, and analyses; and other health...more

11/5/2018  /  ACOs , Ambulatory Surgery Centers , Centers for Medicare & Medicaid Services (CMS) , Department of Health and Human Services (HHS) , Drug Pricing , Food and Drug Administration (FDA) , HRSA , Medicare Part B , Outpatient Prospective Payment System (OPPS) , Pharmaceutical Industry , Prescription Drugs , Section 340B

Alston & Bird Healthcare Week in Review

Alston & Bird’s Week in Review provides a synopsis of the latest news in health care regulations, notices, and guidance; federal legislation and Congressional committee action; reports, studies, and analyses; and other health...more

10/22/2018  /  Advertising , Centers for Medicare & Medicaid Services (CMS) , Food and Drug Administration (FDA) , GAO , Pharmaceutical Industry , Prescription Drugs , Television Commercials

Alston & Bird Healthcare Week in Review

Alston & Bird’s Week in Review provides a synopsis of the latest news in health care regulations, notices, and guidance; federal legislation and Congressional committee action; reports, studies, and analyses; and other health...more

10/8/2018  /  Dietary Supplements , Food and Drug Administration (FDA) , Medical Devices , Pharmaceutical Industry , Prescription Drugs

Alston & Bird Healthcare Week in Review

Alston & Bird’s Week in Review provides a synopsis of the latest news in health care regulations, notices, and guidance; federal legislation and Congressional committee action; reports, studies, and analyses; and other health...more

10/1/2018  /  Centers for Disease Control and Prevention (CDC) , Centers for Medicare & Medicaid Services (CMS) , Federal Food Drug and Cosmetic Act (FFDCA) , Food and Drug Administration (FDA) , Medicare , Medicare Part D , Pharmaceutical Industry , Prescription Drug Coverage , Prescription Drugs , Section 503

Alston & Bird Healthcare Week in Review

Alston & Bird’s Week in Review provides a synopsis of the latest news in health care regulations, notices, and guidance; federal legislation and Congressional committee action; reports, studies, and analyses; and other health...more

9/24/2018  /  Centers for Medicare & Medicaid Services (CMS) , Federal Food Drug and Cosmetic Act (FFDCA) , Food and Drug Administration (FDA) , Health Care Providers , Pharmaceutical Industry

Alston & Bird Healthcare Week in Review

Alston & Bird’s Week in Review provides a synopsis of the latest news in health care regulations, notices, and guidance; federal legislation and Congressional committee action; reports, studies, and analyses; and other health...more

9/17/2018  /  Federal Food Drug and Cosmetic Act (FFDCA) , Food and Drug Administration (FDA) , Medical Devices , Pharmaceutical Industry , Prescription Drugs

Alston & Bird Healthcare Week in Review

Alston & Bird’s Week in Review provides a synopsis of the latest news in health care regulations, notices, and guidance; federal legislation and Congressional committee action; reports, studies, and analyses; and other health...more

9/4/2018  /  Department of Veterans Affairs , Food and Drug Administration (FDA) , HRSA , Opioid , Pharmaceutical Industry , Prescription Drugs , Veterans

Alston & Bird Healthcare Week in Review

Alston & Bird’s Week in Review provides a synopsis of the latest news in health care regulations, notices, and guidance; federal legislation and Congressional committee action; reports, studies, and analyses; and other health...more

7/30/2018  /  Centers for Medicare & Medicaid Services (CMS) , Department of Health and Human Services (HHS) , Food and Drug Administration (FDA) , Generic Drugs , Health Care Providers , Medical Device User Fee Program (MDUFA IV) , Outpatient Prospective Payment System (OPPS) , Pharmaceutical Industry , SAMHSA

Alston & Bird Healthcare Week in Review

Alston & Bird’s Week in Review provides a synopsis of the latest news in health care regulations, notices, and guidance; federal legislation and Congressional committee action; reports, studies, and analyses; and other health...more

7/23/2018  /  Abbreviated New Drug Application (ANDA) , Biosimilars , Centers for Medicare & Medicaid Services (CMS) , Department of Health and Human Services (HHS) , Food and Drug Administration (FDA) , GAO , Labeling , Medicare , Pharmaceutical Industry , SAMHSA , Section 340B

Alston & Bird Healthcare Week in Review

Alston & Bird’s Week in Review provides a synopsis of the latest news in health care regulations, notices, and guidance; federal legislation and Congressional committee action; reports, studies, and analyses; and other health...more

7/2/2018  /  Centers for Medicare & Medicaid Services (CMS) , Department of Health and Human Services (HHS) , Food and Drug Administration (FDA) , HRSA , Opioid , Pharmaceutical Industry , Physicians , Prescription Drugs , Section 340B

Alston & Bird Healthcare Week in Review

Alston & Bird’s Week in Review provides a synopsis of the latest news in health care regulations, notices, and guidance; federal legislation and Congressional committee action; reports, studies, and analyses; and other health...more

6/25/2018  /  Association Health Plans , Biologics , Centers for Medicare & Medicaid Services (CMS) , Department of Health and Human Services (HHS) , Department of Labor (DOL) , Employee Benefits , Employee Retirement Income Security Act (ERISA) , Food and Drug Administration (FDA) , Medicaid , Medicare , Opioid , Pharmaceutical Industry , SAMHSA , Substance Abuse

Alston & Bird Healthcare Week in Review

Alston & Bird’s Week in Review provides a synopsis of the latest news in health care regulations, notices, and guidance; federal legislation and Congressional committee action; reports, studies, and analyses; and other health...more

6/18/2018  /  Biologics , Centers for Medicare & Medicaid Services (CMS) , Department of Health and Human Services (HHS) , Drug Pricing , Food and Drug Administration (FDA) , Medical Devices , Pharmaceutical Industry , Prescription Drugs , SAMHSA

Alston & Bird Healthcare Week in Review

Alston & Bird’s Week in Review provides a synopsis of the latest news in health care regulations, notices, and guidance; federal legislation and Congressional committee action; reports, studies, and analyses; and other health...more

6/11/2018  /  Biosimilars , Centers for Medicare & Medicaid Services (CMS) , Department of Health and Human Services (HHS) , Food and Drug Administration (FDA) , Health Care Providers , Pharmaceutical Industry , Prescription Drugs

Alston & Bird Healthcare Week in Review

Alston & Bird’s Week in Review provides a synopsis of the latest news in health care regulations, notices, and guidance; federal legislation and Congressional committee action; reports, studies, and analyses; and other health...more

5/21/2018  /  Centers for Medicare & Medicaid Services (CMS) , Department of Health and Human Services (HHS) , Food and Drug Administration (FDA) , GAO , Generic Drugs , HRSA , Institutional Review Board (IRB) , Pharmaceutical Industry , Section 340B

Alston & Bird Healthcare Week in Review

Alston & Bird’s Week in Review provides a synopsis of the latest news in health care regulations, notices, and guidance; federal legislation and Congressional committee action; reports, studies, and analyses; and other health...more

4/30/2018  /  Centers for Medicare & Medicaid Services (CMS) , Department of Health and Human Services (HHS) , EHR , Food and Drug Administration (FDA) , Health Care Providers , Inpatient Prospective Payment System (IPPS) , Medicare , Pharmaceutical Industry , Skilled Nursing Facility

Alston & Bird Healthcare Week in Review

Alston & Bird’s Week in Review provides a synopsis of the latest news in health care regulations, notices, and guidance; federal legislation and Congressional committee action; reports, studies, and analyses; and other health...more

4/9/2018  /  Abbreviated New Drug Application (ANDA) , Centers for Medicare & Medicaid Services (CMS) , Department of Health and Human Services (HHS) , Food and Drug Administration (FDA) , Generic Drugs , HCPCS , HRSA , Medicare Advantage , Medicare Part A , Medicare Part D , Pharmaceutical Industry

Alston & Bird Healthcare Week in Review

Alston & Bird’s Week in Review provides a synopsis of the latest news in health care regulations, notices, and guidance; federal legislation and Congressional committee action; reports, studies, and analyses; and other health...more

4/2/2018  /  Abbreviated New Drug Application (ANDA) , Centers for Medicare & Medicaid Services (CMS) , Department of Health and Human Services (HHS) , Food and Drug Administration (FDA) , Generic Drugs , Pharmaceutical Industry , SAMHSA

Alston & Bird Healthcare Week In Review

I. Regulations, Notices, & Guidance - On February 20, 2018, the Department of Health and Human Services (HHS) issued a proposed rule entitled, Short-Term, Limited-Duration Insurance. The rule contains proposals amending the...more

2/26/2018  /  Department of Health and Human Services (HHS) , Food and Drug Administration (FDA) , Medical Devices , Pharmaceutical Industry , Prescription Drugs

Alston & Bird Healthcare Week in Review

On November 15, 2017, the Food and Drug Administration (FDA) issued a draft guidance entitled, Assessing User Fees Under the Biosimilar User Fee Amendments of 2017. The Biosimilar User Fee Amendments of 2017 (BsUFA II)...more

11/24/2017  /  21st Century Cures Act , Biologics , Biosimilars , BsUFA , Comprehensive Addiction and Recovery Act of 2016 (CARA) , Food and Drug Administration (FDA) , Healthcare , Medical Devices , Medicare , Medicare Advantage , Medicare Part C , Medicare Part D , New Guidance , PACE , Pharmaceutical Industry

A&B Healthcare Week in Review

I. REGULATIONS, NOTICES, & GUIDANCE - On May 6, 2016, the Centers for Medicare & Medicaid Services (CMS) issued an interim final rule entitled, “Patient Protection and Affordable Care Act; Amendments to Special...more

5/18/2016  /  Affordable Care Act , Centers for Disease Control and Prevention (CDC) , Centers for Medicare & Medicaid Services (CMS) , Food and Drug Administration (FDA) , GAO , Managed Care Contracts , Medicare , Medicare Advantage , Medicare Part D , Pharmaceutical Industry , Prescription Drugs , PTAC

A&B Healthcare Week in Review

I. REGULATIONS, NOTICES, & GUIDANCE - On April 15, 2016, the Food and Drug Administration (FDA) issued a proposed rule entitled, “Applications for Approval and Combinations of Active Ingredients Under Consideration for...more

4/21/2016  /  Abbreviated New Drug Application (ANDA) , Affordable Care Act , AHRQ , Centers for Disease Control and Prevention (CDC) , Centers for Medicare & Medicaid Services (CMS) , CGMP , Department of Health and Human Services (HHS) , DSCSA , Food and Drug Administration (FDA) , Health Care Providers , Health Insurance , HRSA , IRS , Legislative Agendas , Medicaid , Medical Devices , Medicare , OIG , Overpayment , Pharmaceutical Industry , Prescription Drugs , Public Health Insurance Marketplace , Tax Liability

A&B Healthcare Week in Review

I. REGULATIONS, NOTICES, & GUIDANCE - On March 24, 2016, the Food and Drug Administration (FDA) issued a guidance entitled, “Draft Guidance for Industry: General Principles for Evaluating the Abuse Deterrence of Generic...more

3/25/2016  /  Affordable Care Act , Biologics , Cancer , CCIIO , Centers for Disease Control and Prevention (CDC) , Centers for Medicare & Medicaid Services (CMS) , Controlled Substances , Controlled Substances Act , DEA , Department of Health and Human Services (HHS) , Department of Justice (DOJ) , Food and Drug Administration (FDA) , HCPCS , Legislative Agendas , Medicaid , Medical Devices , Medical Reimbursement , Medicare , Medicare Access and CHIP Reauthorization (MACRA) , Medicare Part D , Native American Issues , Opioid , Pharmaceutical Industry , Prescription Drugs , Public Health Insurance Marketplace , Stem cells , Toxic Exposure , Zika
25 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up Log in
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide